← FDA DRUG APPROVALS

FDA ANDA · ANDA209421

OSELTAMIVIR PHOSPHATE

Sponsor: STRIDES PHARMA

APPLICATION
ANDA209421
TYPE
ANDA
ORIGINAL APPROVAL
2018-06-08
LATEST ACTION
2021-07-06
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

OSELTAMIVIR PHOSPHATEPrescription
OSELTAMIVIR PHOSPHATE EQ 45MG BASE · CAPSULE · ORAL
OSELTAMIVIR PHOSPHATEPrescription
OSELTAMIVIR PHOSPHATE EQ 75MG BASE · CAPSULE · ORAL
OSELTAMIVIR PHOSPHATEPrescription
OSELTAMIVIR PHOSPHATE EQ 30MG BASE · CAPSULE · ORAL

Approval history

2021-07-06Labeling · Supplement 6 · standardAP
2021-07-06Labeling · Supplement 3 · standardAP
2018-06-08UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →